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ABSTRACT
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblast-
oma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aque-
ous solubility and undesirable side effects limit its clinical application, including local treatment. We
encapsulated SFN in lipid nanocapsules (LNCs) to overcome these drawbacks. LNCs are nanocarriers
formulated according to a solvent-free process, using only components that have received regulatory
approval. SFN-LNCs had a diameter of 54±1nm, high encapsulation efficiency (>90%), and a drug
payload of 2.11 ± 0.03mg/g of LNC dispersion. They inhibited in vitro angiogenesis and decreased
human U87MG GB cell viability similarly to free SFN. In vivo studies showed that the intratumoral
administration of SFN-LNCs or free SFN in nude mice bearing an orthotopic U87MG human GB xeno-
graft decreased the proportion of proliferating cells in the tumor relative to control groups. SFN-LNCs
were more effective than free SFN for inducing early tumor vascular normalization, characterized by
increases in tumor blood flow and decreases in tumor vessel area. These results highlight the potential
of LNCs as delivery systems for SFN. The vascular normalization induced by SFN-LNCs could be used
to improve the efficacy of chemotherapy or radiotherapy for treating GB.
ARTICLE HISTORY
Received 8 June 2018
Revised 26 July 2018
Accepted 29 July 2018
KEYWORDS
Drug delivery; glioblastoma;
lipid nanocapsules;
sorafenib
Introduction
Glioblastoma (GB) is the most frequent, aggressive, and fatal
type of brain tumor, with a mean 5-year survival rate of less
than 5% (Stupp et al., 2005, 2009). Despite considerable sci-
entific and technological progress, the treatment of GB
remains a major challenge.
Signaling pathways initiated by activated receptor tyrosine
kinases (RTKs), including those for epidermal growth factor
(EGFR), platelet-derived growth factor (PDGFR), or vascular
endothelial growth factor (VEGFR), play a key role in the
growth, invasiveness, and angiogenesis of this tumor and are
attractive therapeutic targets (Chen et al., 2016; Miller &
Wen, 2016; Lin et al., 2017). Several drugs directed against
RTK signaling pathways have been developed. Sorafenib
(NexavarTM, SFN), approved for the treatment of advanced
hepatocellular carcinoma, renal cell carcinoma, and thyroid
cancer, is one such drug (Wilhelm et al., 2006). SFN is a mul-
tikinase inhibitor that acts on cell surface RTKs (e.g. VEGFR-2
and VEGRF-3, PDGFR-b, c-kit, and Flt-3) and downstream
intracellular serine/threonine kinases (e.g. Raf-1, wild-type B-
Raf, and mutant B-Raf). SFN has demonstrated anti-GB activ-
ity in both in vitro and in vivo models, inhibiting cell
proliferation and angiogenesis (Siegelin et al., 2010; Yang
et al., 2010; Carra et al., 2013). However, SFN treatment has
been shown to be of very limited efficacy in patients with
progressive or recurrent GB, either as a monotherapy or in
combination with temozolomide or other targeted drugs,
such as erlotinib (Reardon et al., 2011; Lee et al., 2012; Den
et al., 2013; Peereboom et al., 2013; Zustovich et al., 2013;
Hassler et al., 2014; Hottinger et al., 2014). This may be due,
in part, to the route of SFN administration. The poor solubil-
ity of SFN strongly limits its application for local treatment
and this drug is orally administered in the form of SFN tosyl-
ate tablets. This mode of administration may be effective for
peripheral tumors, such as hepatocellular carcinoma, renal
cell carcinoma, and thyroid cancer, but less so for brain
tumors, due to the low efficiency of SFN passage across the
blood-brain barrier (BBB) (Agarwal et al., 2011). High systemic
doses of this drug are required to obtain effective brain-
tumor concentrations, but the potential adverse events asso-
ciated with the systemic administration of SFN, such as
hand-foot skin reactions, rashes, upper and lower gastro-
intestinal distress, fatigue, and hypertension, rule out this
mode of administration (Brose et al., 2014). Systems for deliv-
ering SFN for local or systemic treatment are, therefore,
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required, to improve the anti-GB activity of this drug. We
recently showed that mesenchymal stromal cells (MSCs) have
the potential to transport SFN to brain tumors following
intranasal administration (Clavreul et al., 2017). However, the
therapeutic effect was modest, probably due to the
pro-tumorigenic properties of the MSCs themselves, which
may counteract the action of the released SFN. The use of
nanocarriers for the brain tumor delivery of SFN is another
possibility. We studied lipid nanocapsules (LNCs) for SFN
encapsulation because of the advantages they offer over
other types of nanocarriers. These advantages include their
production by a phase-inversion process using generally rec-
ognized as safe (GRAS) excipients, without the use of organic
solvents, their high stability and drug loading capacity, and
the possibility of scaling up their production easily (Huynh
et al., 2009; Saliou et al., 2013). The direct intracranial deliv-
ery of drug-loaded LNCs by stereotaxic injection has yielded
promising results in orthotopic GB models (Allard et al.,
2008, 2009, 2010; Vinchon-Petit et al., 2010; Vanpouille-Box
et al., 2011; Huynh et al., 2012; Balzeau et al., 2013; Danhier
et al., 2015; Lollo et al., 2015; Cikankowitz et al., 2017;
Sehedic et al., 2017). Furthermore, the LNC surface can be
modified by incorporating specific molecules to improve
the brain tumor targeting of these nanovectors (Beduneau
et al., 2007; Laine et al., 2012; Balzeau et al., 2013; Hirsj€arvi
et al., 2014; Lollo et al., 2015; Sehedic et al., 2017).
We describe here the preparation of SFN-loaded LNCs
(SFN-LNCs) and their characterization in terms of size, poly-
dispersity index (PDI), surface charge, drug payload, in vitro
drug release, and storage stability. Their toxicity against
the U87MG GB cell line and effects on angiogenesis were
evaluated in vitro and in vivo.
Materials and methods
Chemicals
SFN powder was purchased from LC Laboratories (Wobern,
USA). Oil solubilizers and excipients were provided by
Gattefosse S.A (Saint-Priest, France). LipoidVR S75-3 (soybean leci-
thin with 70% phosphatidylcholine and 10% phosphatidyletha-
nolamine) and KolliphorVR HS15 (mixture of free polyethylene
glycol 660 and polyethylene glycol 660 hydroxystearate) were
gifts from Lipoid Gmbh (Ludwigshafen, Germany) and BASF
(Ludwigshafen, Germany), respectively. NaCl was purchased
from Prolabo VWR International (Fontenay-sous-Bois, France).
Purified water was obtained with a MilliQ185 System (Millipore,
Paris, France). Formic acid, acetic acid, acetonitrile, dimethylsulf-
oxide (DMSO), methanol, and HPLC-grade tetrahydrofurane
(THF) were purchased from Sigma-Aldrich (Saint-Quentin
Fallavier, France) and Carlo Erba reagents (Val-de-Reuil, France).
Analytical methods
Analysis of SFN by high-performance liquid chromatog-
raphy (HPLC-UV)
An HPLC-UV method was used to quantify SFN, as previously
described (Clavreul et al., 2017). Briefly, HPLC was performed
on a Waters modular system (600/717/996/2414) (Waters,
Saint-Quentin-en-Yvelynes, France) with a SunFireVR C18 col-
umn (150 4.6mm; 5 lm) at 37 C. SFN was eluted with an
isocratic mobile phase (acetonitrile/methanol/1% acetic acid,
at a ratio of 35:38:27), at a flow rate of 1mL/min, with moni-
toring at 266 nm. The chromatograms were recorded and
integrated with Empower 3 software (Waters). The response
was linear from 0.5 to 32 lg/mL.
Analysis of SFN by liquid chromatography tandem-mass
spectrometry (LC-MS/MS)
A specific LC-MS/MS method was previously developed
(Clavreul et al., 2017). Briefly, chromatography was performed
on a Waters AllianceVR 2695 system with an UptisphereVR 5
0DB (150 2.0mm) column, at 25 C, using an isocratic mix-
ture of 0.1% formic acid in water/0.1% formic acid in aceto-
nitrile: 20/80 (v/v) at a flow rate of 0.3mL/min. Detection
was performed using electrospray ionization in positive ion
multiple reaction monitoring (MRM) mode, with the mass
transition, m/z 465 ! 270. Quantification was achieved with
QuantLynxVR (Waters), by comparing the observed peak area
ratios of SFN samples with a calibration curve obtained
under the same experimental conditions. The calibration
curve was linear in the concentration range of
50–1000 ng/mL.
Solubility studies
A screening study was performed to determine the exci-
pients likely to solubilize SFN. We added 10mg SFN to 1 g
excipient. Preparations were vortexed for 5min, sonicated for
45min, and centrifuged. Supernatants were extracted and
analyzed using HPLC-UV.
LNC formulation
SFN-LNCs were prepared according to the phase-inversion
temperature method (Heurtault et al., 2002). SFN was first
solubilized in TranscutolVR HP (0.7 g), by vortexing for 5min.
LabrafacVR WL1349 (0.4 g), LabrafilVR M1944CS (1 g) and
LipoïdVR S75-3 (150mg) were then added. The compounds
were heated on a hot plate at 80 C, with shaking at
1200 rpm, until the LipoïdVR S75-3 was completely dissolved.
Once the mixture returned to room temperature, the other
compounds of the formulation (i.e., water, NaCl, and
KolliphorVR HS15 (1.8 g, 0.1 g, and 1 g, respectively)) were
introduced. Three cycles of progressive heating to 90 C and
cooling to 60 C were then carried out, and, at 75 C during
the last cycle, an irreversible shock was induced by adding
5mL of water at 0 C. The LNC suspension was subjected to
slow magnetic stirring for 5min at room temperature. The
formulation was filtered through a MinisartVR filter with
0.2 mm pores (Sartorius, Goettingen, Germany) and stored at
4 C for further characterization. Blank LNCs (B-LNCs) were
formulated in the same way but with the omission of SFN.
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LNC characterization
Particle size and zeta potential measurements
The size, PDI, and charge distribution of LNCs were measured
using dynamic light scattering (DLS) on a ZetasizerVR Nano
series DTS 1060 (Malvern Instruments S.A., Worcestershire,
UK). The PDI was used to estimate the size distribution.
A PDI value <0.2 indicates a unimodal size distribution.
LNCs were diluted 1:60 (v/v) in deionized water, and three
consecutive measurements were performed.
Encapsulation efficiency and drug loading
Drug loading was carried out using HPLC-UV, as described
above. Three samples were prepared by dissolving 10mL filtered
SFN-LNCs in 990mL 79/20 (v/v) methanol/THF and then filtering
through a Millex-LG filter unit (0.2mm pores). SFN loading was
calculated and expressed in mg of SFN/g of LNC dispersion.
Encapsulation efficiency (%) was determined by dividing the
experimental drug loading by the theoretical drug loading.
Storage stability studies
The stability of SFN-LNC formulations (n¼ 4) was evaluated
after storage at 4 C for 4 months. The particle size, PDI, zeta
potential, and drug payload of the samples were determined
after filtration through a MinisartVR filter with 0.2 mm pores
(Sartorius), as described above.
Evaluation of drug-release profile
SFN-LNCs (n¼ 4) were diluted 1:170 (v/v) in DPBS (Ozyme, St
Quentin-en-Yvelines, France) and incubated at 37 C with shak-
ing. A 1 mL release medium sample was withdrawn at intervals
of 0.5, 1, 2, 3, 8, 24, 48, and 120h and replaced with 1 mL
DPBS. Samples were filtered through a MinisartVR filter with
0.2mm pores (Sartorius), to remove free precipitated SFN. The
cumulative release of SFN from LNCs was determined indir-
ectly, by evaluating SFN loading by the LC-MS/MS method.
In vitro studies
Cell culture
The human GB cell line U87MG was obtained from the ATCC
(LGC Promochem, Molsheim, France) and expanded in
DMEM-high glucose medium (DMEM-HG, Ozyme) containing
10% FBS (Fisher Scientific, Illkirch, France) and 1% antibiotics
(Sigma-Aldrich). Human umbilical vein endothelial cells
(HUVECs) were purchased from Lonza (Verviers, Belgium).
Cells were cultured, according to the supplier’s instructions,
in endothelial cell growth medium-2 (EGM-2), corresponding
to endothelial basal medium-2 (EBM-2) containing the sup-
plements and growth factors of the EGM-2 SingleQuotTM kit
(Lonza). U87MG cells and HUVECs were maintained under an
atmosphere containing 5% CO2 (37 C), in a humidified incu-
bator, until they reached 80% confluence.
U87MG viability assay
U87MG (5 103 cells/cm2) were plated in 96-well plates.
After 48 h, the culture medium was removed, and the cells
were treated with SFN and SFN-LNCs, at concentrations of
0.001–100 mM. B-LNCs were also tested with the same excipi-
ent concentration. After 96 h, the medium was removed and
the plates were stored at 80 C until the assays were car-
ried out. Cell survival was estimated with the CyQUANTVR cell
proliferation assay kit, according to the manufacturer’s
instructions (Fisher Scientific).
Endothelial cell tube-formation assay
HUVECs (5 104 cells/cm2) were incubated in CorningVR
MatrigelVR basement membrane matrix-coated 96-well plates
(VWR International, Fontenay-sous-Bois, France) for 16 h in
EGM-2, with or without SFN, B-LNCs, or SFN-LNCs. The endo-
thelial tubes formed were photographed and quantified. The
degree of tube formation was assessed by manual counting
of the number of tube-like structures in four wells for each
set of conditions.
In vivo studies
A scheme for the protocol used in this study is presented in
Figure S1.
Intratumor administration of SFN-LNCs in the U87MG
GB model
Female Swiss nude mice (8–10-weeks old) were obtained from
Charles River Laboratories (L’Arbresle, France). The protocol was
approved by the Committee for the Ethics of Animal
Experiments of the ‘Pays de la Loire’ (Permit no. 01785.01).
Animals were anesthetized by an intraperitoneal injection of
xylazine (13mg/kg body weight) and ketamine (100mg/kg
body weight) and positioned in a Kopf stereotaxic instrument.
On day 0, U87MG cells (5 104) in 5lL HBSS containing Ca2þ
and Mg2þ were injected into the right striatum of the mice
[coordinates: 2.1mm lateral to the bregma and 0.5mm anterior
and 3mm interior to the outer border of the cranium]. On day
9, the mice were assigned to four groups and received an injec-
tion, by convection-enhanced delivery (CED) (5mL; 0.5mL/min) at
the same coordinates of (a) HBSS with Ca2þ and Mg2þ (n¼ 5);
(b) B-LNCs (n¼ 5); (c) SFN-LNCs (n¼ 7, 3.5mg); or (d) SFN (n¼ 5,
3.5mg). Tumor volume and perfusion were measured on day 13.
Mice were killed on day 16, and the number of proliferating
Ki67þ cells and the area of CD31þ vessels in the U87MG tumor
was analyzed. Brains were snap-frozen in liquid nitrogen-cooled
isopentane and stored at 80 C. Coronal sections of the brain
were cut at 10mm intervals and collected on silane-treated
slides. For histological analysis, ethanol (95%)/acetic acid
(5%)-fixed brain sections were stained with Mayer’s hematoxylin
solution and permanently mounted.
In vivo measurement of brain tumor volume
and perfusion
MRI was performed with a 7T scanner (Biospec 70/20 Avance III,
Bruker, Wissembourg, France), equipped with a BGA12S gradient
system (675mT/m), under isoflurane anesthesia (1.5–0.5%, O2:
0.5 L/min). Body temperature was maintained at 36.5–37.5 C
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with a feedback-regulated heating pad during the entire imag-
ing protocol. Tumor volume was assessed over time with a 1H
cryoprobe and rapid acquisition with a relaxation enhancement
(RARE) sequence [TR¼ 3200ms; effective echo time
(TEeff)¼ 21.3ms; acceleration factor¼ 4; FOV¼ 2 2cm; matrix
256 256; 11 contiguous slices of 0.5mm, Nex¼ 1]. Volumes
were calculated from manually drawn regions of interest (ROI).
Tumor perfusion was assessed by segmented fast imaging
with a steady-state precession arterial spin labeling sequence
(FISP-ASL), as previously described (Lemaire et al., 2016).
Homogeneous radiofrequency excitation was achieved using a
proton volume resonator (diameter 87mm, homogeneous
length 80mm) and signal reception was performed with an
actively decoupled phased-array surface coil (4 channels). Blood
flow was measured from two T1 maps acquired once with slice-
selective inversion and once with global inversion (Kober et al.,
2004). A series of 40 gradient echoes were acquired after the
inversion pulse to acquire T1 maps (flip angle¼ 8, echo time-
¼ 1.8ms, field of view¼ 18 18mm, matrix size¼ 128 128,
excitation hermite pulse duration¼ 800 ls, inversion hyperbolic
secant pulse duration¼ 15ms, imaging slice thickness¼ 1.5mm,
labeling slice thickness¼ 3.9mm, with the first echo started
20ms after the inversion pulse, and a 60ms interval among
echoes). Thirty-two segments were used to fill k-space. A repeti-
tion delay of 13 s was introduced after the acquisition of a set
of gradient echoes to allow for full relaxation between two
inversion pulses. The total measurement time was approxi-
mately 14min. ROIs were manually outlined in the tumor core,
the surrounding tissue, and out to the contralateral side of the
brain for comparison. Blood flow in these ROIs was calculated
using ParaVision 5.1 software (Bruker).
Immunofluorescence
For CD31 and Ki67 expression analyses, brain cryosections
were allowed to dry in air, rehydrated in DPBS, and fixed by
incubation for 10min in 4% PFA, pH 7.4, at 4 C. Nonspecific
binding was blocked by incubating the sections in 4% BSA
and 10% normal goat serum in DPBS. The sections were incu-
bated overnight, at 4 C, with isotype controls and primary
antibodies against endothelial cells (mouse CD31, BD
Biosciences, Le Pont de Claix, France) and proliferative cells
(Ki67, Agilent Technologies, Les Ulis, France). The primary anti-
bodies were detected with biotinylated secondary antibodies,
and the signal was amplified with Alexa Fluor 488 streptavidin
(Interchim, Montluc¸on, France). Nuclei were counterstained
with DAPI (Sigma-Aldrich). Cryosections of four mice from
each group described above (a, b, c, and d) were analyzed
under an AxioscopeVR 2 fluorescence microscope. CD31þ and
Ki67þ cells were counted with the MetaView computerized
image-analysis system in six brain cryosections per mouse,
corresponding to three areas of the tumor approximately
400mm apart (Figure S1). Five fields per cryosection, at 200
magnification, were randomly selected for each tumor.
Statistics
Results are expressed as the mean± SEM (standard error of
the mean). The Mann–Whitney U-test and one-way ANOVA,
followed by Dunnett’s post hoc test for multiple comparisons
were used for statistical analyses. Differences were consid-
ered to be significant if the p-value was <.05.
Results
Production of SFN-LNCs
Studies of SFN solubility
SFN solubility in six different excipients (five oils and one co-
surfactant), potentially useful for LNC formulation, was ana-
lyzed at 1% (w/w). SFN was soluble only in TranscutolVR HP,
at a maximum rate of 120mg/g (Table 1).
Formulation of SFN-LNCs
Based on the solubility of SFN in TranscutolVR HP and the
results of Roger et al. (2011), a mixture of LabrafacVR WL1349,
LabrafilVR M1944CS, and LipoïdVR S75-3 was used to formulate
LNCs. B-LNCs had a mean diameter of 49 ± 1 nm and narrow
size distribution (PDI¼ 0.11) (Table 2).
We assessed the physicochemical characteristics of SFN-
LNCs (filtration ability, peak number and PDI) as a function of
the amount of SFN (15, 20, 30, 50, and 84mg) dissolved in
TranscutolVR HP (0.7 g). The formulations became increasingly
difficult to filter as the quantity of SFN increased, and particle
size became more heterogeneous and the range of particle
sizes broader (Table S1). We set the amount of SFN used in
the formulation to 20mg on the basis of these observations.
The resulting SFN-LNCs had physicochemical properties similar
to those of B-LNCs and a drug payload of 2.11mg/g of LNC
dispersion with an encapsulation efficiency >90% (Table 2).
In vitro release profile
We then assessed the percentage of SFN released from SFN-
LNCs into DPBS buffer over time (Figure 1). We observed a burst
of SFN release within the first 8h, the dose reaching 11% of
the total SFN. Subsequently, SFN was released in a gradual and
sustained manner: 20% of the initial dose within 120h.
Table 1. Solubility of SFN in various excipients at 1% (w/w).
Excipients Function Solubility
TranscutolVR HP Co-surfactant S
LabrafilVR M1944CS Oil NS
PeceolTM Oil NS
LabrafacVR WL1349 Oil NS
CaptexVR 8000 Oil NS
Oleic acid 99% Oil NS
S: Soluble; NS: not soluble.
Table 2. Characterization of B-LNCs (n¼ 6) and SFN-LNCs (n¼ 17).
Sample Size (nm) PDI Zeta potential (mV) Drug payload (mg/g) Encapsulation efficiency (%)
B-LNCs 49 ± 1 0.11 ± 0.01 7.9 ± 0.4 – –
SFN-LNCs 54 ± 1 0.15 ± 0.01 7.8 ± 0.6 2.11 ± 0.03 105 ± 1
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Storage stability
SFN-LNCs were physically stable at 2–8 C for at least four
months (Table S2). We observed no meaningful change in
mean LNC size, pH, or zeta potential. In addition, there was
no variation in drug payload after four months.
In vitro and in vivo effects of SFN-LNCs
Effect of SFN-LNCs on U87MG tumor cells and endothelial
tube formation
Neither free SFN nor SFN-LNCs altered the growth of U87MG
cells at concentrations below 5 mM (Figure 2(a)). U87MG cell
survival decreased at concentrations above 5 mM, correspond-
ing to an IC50 of 7.39 ± 016 mM for free SFN and
7.56 ± 0.07mM for SFN-LNCs. The viability of U87MG was
unaltered by formulation in B-LNCs, except at the highest
concentration tested. We evaluated the antiangiogenic
properties of SFN-LNCs in a HUVEC tube-formation
assay (Figure 2(b,c)). Treatment with B-LNCs did not affect
EGM-2-induced tube formation, whereas incubation with 5 or
10 mM SFN-LNCs or SFN markedly decreased tube formation,
in a dose-dependent manner (Figure 2(b,c)).
Evaluation of the intratumoral administration of SFN-
LNCs in the orthotopic U87MG GB model
We assessed the effect of intratumoral CED infusion of SFN-
LNCs on U87MG growth and angiogenesis, as described in
Figure S1.
Tumor volume alterations. There was no significant differ-
ence in tumor volume between control vehicle-treated groups
(HBSS and B-LNCs) and SFN-LNC- or SFN-treated groups
4 days after treatment (D13) (HBSS mean¼ 7.2 ±0.6mm3, B-
LNC mean¼ 9.1 ±0.9mm3, SFN-LNC mean¼ 9.5 ±0.9mm3,
SFN mean¼ 7.4 ±0.7mm3) (Figure 3(a)). Control vehicle-, SFN-
LNC-, and SFN-treated-tumors had similar growth rates
between MRI (D13) and histological and immunofluorescence
analyses (D16) (data not shown).
Tumor perfusion analyses. We determined tumor perfu-
sion from ASL-MRI perfusion maps, to assess the tumor
microvasculature. In all animals, tumor blood flow (TBF) was
weaker than that in the surrounding tissue or contralateral
brain tissue (Figure 3(b,c)). Blood flow in the tumor core of
mice treated with SFN-LNCs was slightly stronger than that
in the tumor core in control vehicle-treated mice and SFN-
treated mice (Figure 3(b,c)) (HBSS mean¼ 50± 3mL/100 g/
min, B-LNC mean¼ 51 ± 2mL/100 g/min, SFN-LNC
mean¼ 62 ± 4mL/100 g/min, SFN mean¼ 49± 3mL/100 g/
min, p< .05: SFN-LNC vs. HBSS).
Analyses of the immunofluorescence of intratumoral
Ki671 cells and CD311 vessels. SFN-LNC or SFN treatment
decreased the number of intratumoral Ki67þ cells in
U87MG-bearing mice relative to control vehicle-treated mice 7Figure 1. SFN release profile from LNCs in DPBS (n¼ 4).
Figure 2: Effect of SFN-LNCs on U87MG tumor cell viability and the ability of HUVECs to form tube-like structures. (a) U87MG cell viability following exposure to
various concentrations of B-LNCs, SFN-LNCs, or SFN (0.001–100lM). Data are expressed as the means ± SEM (n¼ 4). The results obtained for U87MG cells grown in
culture medium alone were considered to correspond to 100% survival (p< .05 for B-LNCs, SFN-LNCs, or SFN vs. culture medium alone, Mann-Whitney U-test).
(b and c) Formation of tube-like structures by HUVEC following treatment with B-LNCs, SFN-LNCs, or SFN (5 or 10lM). (b) Angiogenesis was quantified by manually
counting the number of tube-like structures. Results are presented as means ± SEM. The number of tube-like structures obtained in EGM-2 alone was considered to
correspond to 100% (p< .05 for SFN-LNCs or SFN vs. EGM-2, Mann–Whitney U-test). (c) Representative phase-contrast micrographs of HUVEC tube formation on
Matrigel 16 h after treatment with 5 mM B-LNCs, SFN-LNCs, or SFN. The positive control corresponded to EGM-2 medium alone (scale bar¼ 100mm).
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days after administration (Figure 4(a,b)) (HBSS mean¼ 671±24
Ki67þ cells/mm2, B-LNC mean¼ 629±10 Ki67þ cells/mm2,
SFN-LNC mean¼ 537±22 Ki67þ cells/mm2, SFN mean-
¼ 556±11 Ki67þ cells/mm2, p< .05: SFN-LNC or SFN vs. HBSS).
SFN-LNC treatment resulted in a smaller tumor vessel area
than HBSS, B-LNC, or free SFN treatment (Figure 4(a,c)) (HBSS
mean¼ 130±9 mm2, B-LNC mean¼ 124±6 mm2, SFN-LNC
mean¼ 105±5 mm2, SFN mean¼ 128±6 mm2, p< .05: SFN-
LNC vs. HBSS). Control vehicle-, SFN-LNC-, and SFN-treated ani-
mals had similar numbers of tumor vessels (data not shown).
Discussion
SFN has been shown to be a potential targeted molecular
therapeutic agent for various solid tumors, including GB.
It targets RTKs and the RAF/MEK/ERK pathway, thereby
acting as a combined antiangiogenic and antitumorigenic
drug. However, poor solubility in water and undesirable side
effects limit the clinical applications of SFN, even for local
treatment. New strategies are required to overcome these
drawbacks. Nanoformulations of SFN are of potential interest,
as they combine the intrinsic toxicity of the drug with a
nanodelivery approach. Many studies have assessed the use
of SFN encapsulated or entrapped in various nanocarriers,
including polymeric carriers (Zhang et al., 2013; Craparo
et al., 2014; Gao et al., 2015; Li et al., 2015; Liu et al., 2015,
2016; Lin et al., 2016; Yang et al., 2016), lipid-based carriers
(Zhang et al., 2014; Bondı et al., 2015; Grillone et al., 2015;
Liu et al., 2015; Xiao et al., 2016; Yang et al., 2016; Mo et al.,
2018; Benizri et al., 2018), and polymer-lipid hybrid nanopar-
ticles (Zhang et al., 2016, 2017). These nanocarriers have
given promising results in the liver and gastric cancer mod-
els. However, most of these formulations have major draw-
backs, such as the presence of organic solvents or toxic
compounds, preventing their clinical use. Here, we encapsu-
lated SFN in solvent-free LNCs, which were produced
exclusively from GMO-free and GRAS excipients (Hureaux
et al., 2009, 2010; Le Roux et al., 2017).
We determined the solubility of SFN in various LNC for-
mulation constituents. Only TranscutolVR HP was able to dis-
solve SFN. As this compound is a co-surfactant, LabrafacVR
WL1349 and LabrafilVR M1944CS were added to constitute the
oily phase of the formulation. SFN-LNCs have a PDI <0.2,
indicating monodispersity, and a mean particle size of
54 ± 1 nm. The surface charge on SFN-LNCs was negative,
favoring the dispersion of LNCs rather than their aggrega-
tion. The encapsulation efficiency of SFN-LNCs was >90%,
indicating that the SFN was almost completely entrapped
within the LNCs. SFN-LNCs were stable for over 4 months at
4 C, with no change in characteristics. After 5 days in DPBS
buffer, approximately 20% of the SFN was released. This
slow-release profile suggests that most of the SFN remained
associated with the LNCs, which may be beneficial, as it
would allow sufficient time for cells to capture the loaded
LNCs. High encapsulation efficiency and slow drug release
have also been reported for liposomal formulations of SFN
(Liu et al., 2015; Mo et al., 2018).
SFN-LNCs had cytostatic effects against U87MG tumor cells
and endothelial cells similar to those of free SFN, suggesting
that SFN activity is conserved during LNC encapsulation. We
evaluated the in vivo effect of SFN-LNCs in nude mice bearing
an orthotopic human U87MG GB xenograft, after their intratu-
moral administration by CED. CED has the advantage of
bypassing the BBB and results in a greater volume of distribu-
tion than a bolus injection (Ndesendo, 2015). The combination
of LNCs with the CED technique has yielded promising results
in orthotopic GB models for the delivery of therapeutic agents,
such as lipophilic complexes of rhenium-188 (188Re-SSS) (Allard
et al., 2008; Vanpouille-Box et al., 2011; Cikankowitz et al.,
2017; Sehedic et al., 2017), ferrociphenol (Allard et al., 2009,
2010; Huynh et al., 2012), paclitaxel (Vinchon-Petit et al., 2010;
Balzeau et al., 2013; Lollo et al., 2015), and anti-EGFR and anti-
Galectin-1 siRNAs (Danhier et al., 2015). We were, particularly,
interested in detecting early vascular changes in response to
Figure 3. Effect of SFN-LNCs on tumor volume and perfusion in U87MG-bear-
ing mice 4 days after treatment (D13). (a) Tumor volume distribution in each
group, calculated from MRI images. (b) Perfusion MRI images of B-LNC- and
SFN-LNC-treated U87MG glioma-bearing mice (scale bar = 1 mm). T2-weighted
morphological images are shown in the top panels (i) and perfusion maps in
the bottom panels (ii). (c) Graph showing blood-flow values in the tumor core,
the surrounding tissue, and the contralateral striatum. Blood flow (mL/100 g/
min) was measured by the ASL perfusion MRI method (p<.05 for SFN-LNCs
vs. HBSS, one-way ANOVA followed by Dunnett’s post hoc test for multiple
comparisons).
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SFN-LNCs, as endothelial cells are highly sensitive to SFN. We,
thus, performed ASL-MRI, a noninvasive and quantitative tech-
nique that measures perfusion by magnetically labeling water
as a freely diffusible endogenous tracer (Silva et al., 2000), on
large established U87MG tumors (approximately 8mm3). This
technique has already been used in other studies, to evaluate
early antiangiogenic treatment responses for brain tumors in
humans (Fellah et al., 2011; Andre et al., 2015) and rodents
(Rajendran et al., 2014; Towner et al., 2015; Yun et al., 2016;
Ziegler et al., 2017). Blood flow in the tumor core was weaker
than in normal brain tissue, consistent with the results of Sun
et al. (2004). Such an impairment of blood flow is frequently
described in GB, due to a dilated, tortuous, disorganized, and
leaky vasculature (Boucher et al., 1996; Jain, 2001; Chauhan
et al., 2011). Four days after treatment, perfusion in the
tumor core of animals treated with SFN-LNCs was greater
than in control animals and animals treated with SFN
alone. The SFN-LNC-treated group had a TBF value of
62±4mL/min/100g, whereas the HBSS control group had a
TBF value of 50±3mL/min/100g. This increase in blood flow
was localized exclusively to the tumor core. Blood flow was
not altered in the surrounding tissue or in the contralateral stri-
atum. TBF is known to be dependent on tumor size, regardless
of the type of solid tumor (Kallinowski et al., 1989; Hwang
et al., 2015; Lemaire et al., 2016). Lemaire et al. (2016) observed
a decrease in TBF of about 3mL/min/100g for every 1mm3
increase in tumor volume. Mean tumor size was 9.5±0.9mm3
and 7.2±0.5mm3 for the LNC-SFN-treated and HBSS control
groups, respectively. Thus, the increase in TBF observed in the
LNC-SFN-treated group was not due to a decrease in tumor
volume. In addition to the increase in perfusion with SFN-LNC
treatment, we observed a decrease in tumor vessel area. These
data suggest that the SFN-LNCs may have normalized abnor-
mal vessel structures, potentially leading to an increase in per-
fusion. Vessel normalization following treatment with SFN or
other RTK inhibitors has already been described for various
cancers (Wilhelm et al., 2006; Sorensen et al., 2012; Batchelor
et al., 2007, 2013; Navis et al., 2013). We observed no such vas-
cular changes following the treatment of U87MG-bearing mice
with free SFN, highlighting the potential of SFN-LNCs. This may
be due to the capacity of LNCs to improve SFN retention
within the tumor. The prolonged retention of LNCs in brain
tumors following intratumoral CED administration
was previously reported in a study of LNCs loaded with 188Re-
SSS (LNC188Re-SSS) (Vanpouille-Box et al., 2011; Cikankowitz
et al., 2017). Most (70%) of the 188Re-SSS activity was present
in the tumor region 24h after LNC 188Re-SSS injection, whereas
free 188Re-perrhenate was rapidly eliminated in the urine and
feces. In addition to inducing early vascular changes, SFN-LNC
treatment reduced the number of proliferative Ki67þ cells in
the tumor. We also observed this effect after treatment with
free SFN, probably due to the faster uptake of free SFN by
tumor cells than by endothelial cells. Despite the increase in
tumor perfusion and the decreases in tumor vessel area and
the number of Ki67þ cells achieved with SFN-LNCs, these
effects were not sufficient to modify the growth rate of
U87MG tumors. It should be noted that we treated large estab-
lished U87MG tumors, in this study, to allow perfusion analy-
ses, which require a tumor thickness of at least 1.5mm. This
condition may not be compatible with the achievement of a
therapeutic effect, given the aggressiveness of U87MG tumors
(median survival of approximately 24days following the intra-
striatal administration of 5 104 U87MG cells). Furthermore,
the dose of SFN-LNCs injected may not be sufficient to modify
Figure 4. Effect of SFN-LNCs on Ki67þ cell number and CD31þ vessel area. (a) Immunofluorescence staining for Ki67 and CD31 in the tumor on day 16 in each
group of animals (scale bar¼ 100lm). (b and c) Quantitative results for Ki67 and CD31 immunofluorescence. Results are expressed as the mean number of Ki67þ
cells per mm2 ± SEM (b) or CD31þ vessel area ± SEM (c) (p< .05 vs. HBSS, one-way ANOVA followed by Dunnett’s post hoc test for multiple comparisons).
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U87MG tumor growth. Siegelin et al. (2010) observed that the
daily treatment of U87MG-bearing mice with SFN (100mg/kg)
administered by intraperitoneal injection resulted in an inhib-
ition of tumor-cell proliferation and lower levels of angiogen-
esis, resulting in prolonged survival in mice. We injected only
one dose of SFN-LNCs (3.5mg/mouse), a lower dose than that
used in the study by Siegelin et al., corresponding to about
2mg/mouse/day. A repeated-injection regimen is probably
required for SFN-LNCs, to have an effect on U87MG tumor
growth. However, CED is an invasive method, making repeated
treatment difficult. In a clinical context, the systemic adminis-
tration of SFN-LNCs would be simpler, less costly, and more
compatible with long-term treatment. The intravenous route is
the route most frequently used for LNC administration (Huynh
et al., 2011; Hirsj€arvi et al., 2014; Laine et al., 2014). Owing to
the nonspecific uptake of LNCs by the mononuclear phagocyte
system and the presence of the BBB, obtaining an effective
response to treatment following the systemic delivery of drug-
loaded LNCs remains challenging (Huynh et al., 2009; Roger
et al., 2011; Karim et al., 2016). Strategies for improving vascu-
lar function in GB have been reported to provide a window of
opportunity for enhancing the efficacy of chemotherapy or
radiotherapy (Jain, 2005). For example, the delivery of temozo-
lomide in a preclinical intracerebral model of glioma increased
after treatment with the angiogenesis inhibitor SU5416, which
restored the capillary architecture (Ma et al., 2003). Wang et al.
(2015) showed that GB-bearing mice treated with irinotecan in
combination with bevacizumab, an antibody against VEGF, sur-
vived longer than those treated with irinotecan alone. Thus,
SFN-LNCs could be used to improve the efficacy of other
chemotherapy treatments.
Conclusion
We demonstrate here the successful encapsulation of SFN in
LNCs by a phase-inversion process, without the use of
organic solvents. SFN-LNCs displayed cytotoxic activity
against human U87MG GB cells and endothelial cells in vitro,
similar to that observed with free SFN. The intratumoral CED
administration of SFN-LNCs to U87MG-bearing mice
decreased the proportion of proliferating cells and induced
an early increase in tumor blood flow, associated with a
decrease in tumor vessel area consistent with the induction
of a vascular normalization process. The induction of this
process by SFN-LNCs suggests that these nanocarriers could
potentially be used to enhance the efficacy of chemotherapy
or radiotherapy for treating GB. Further studies are required
to evaluate and optimize dosing and schedule for effective
SFN-LNC combinations with other drugs or radiotherapy.
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